Diagnosis, treatment and prevention of renal diseases in HIV infected patients. Recommendations of the Spanish AIDS Study Group/National AIDS Plan;Diagnóstico, tratamiento y prevencin de las alteraciones renales en pacientes con infeccin por el virus de la inmunodeficiencia humana. Recomendaciones del Grupo de Estudio del Sida/Plan Nacional sobre el Sida

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 8, 2010, Pages

  Gutiérrez, Félix ^a   Polo, Rosa ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Secretaria del Plan Nacional sobre el Sida   (Spain)

Author keywords

Chronic kidney disease; Dialysis; Guidelines; Human immunodeficiency virus; Renal failure; Renal transplantation

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CIDOFOVIR; COTRIMOXAZOLE; FOSCARNET; PENTAMIDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC HEPATITIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIALYSIS; GLOMERULUS FILTRATION; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY BIOPSY; KIDNEY NECROSIS; KIDNEY TRANSPLANTATION; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

DECISION TREES; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS;

EID: 77957555799     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.09.012     Document Type: Conference Paper

References (152)

1. E.J. Schwartz, L.A. Szczech, M.J. Ross, M.E. Klotman, J.A. Winston, and P.E. Klotman Highly active antiretroviral therapy and the epidemic of HIV end-stage renal disease J Am Soc Nephrol 16 2005 2412 2420
2. T.K. Rao, E.A. Friedman, and A.D. Nicastri The types of renal disease in the acquired immunodeficiency syndrome N Engl J Med 316 1987 1062 1068
3. L.A. Szczech, D.R. Hoover, J.G. Feldman, M.H. Cohen, S.J. Gange, and L. Gooze Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy Clin Infect Dis 39 2004 1199 1206
4. C.M. Wyatt, J.A. Winston, C.D. Malvestutto, D.A. Fishbein, I. Barash, and A.J. Cohen Chronic kidney disease in HIV infection: An urban epidemic AIDS 21 2007 2101 2103
5. A. Mocroft, O. Kirk, J. Gatell, P. Reiss, P. Gargalianos, and K. Zilmer Chronic renal failure among HIV-1-infected patients AIDS 21 2007 1119 1127
6. L.A. Szczech, S.J. Gange, H.C. Van der, J.A. Bartlett, M. Young, and M.H. Cohen Predictors of proteinuria and renal failure among women with HIV infection Kidney Int 61 2002 195 202
7. L.A. Szczech, C. Grunfeld, R. Scherzer, J.A. Canchola, H.C. Van der, and S. Sidney Microalbuminuria in HIV infection AIDS 21 2007 1003 1009
8. C.M. Wyatt, R.R. Arons, P.E. Klotman, and M.E. Klotman Acute renal failure in hospitalized patients with HIV: Risk factors and impact on in-hospital mortality AIDS 20 2006 561 565
9. N. Franceschini, S. Napravnik, J.J. Eron Jr, L.A. Szczech, and W.F. Finn Incidence and etiology of acute renal failure among ambulatory HIV-infected patients Kidney Int 67 2005 1526 1531
10. R.M. Selik, R.H. Byers Jr., and M.S. Dworkin Trends in diseases reported on US death certificates that mentioned HIV infection, 19871999 J Acquir Immune Defic Syndr 29 2002 378 387
11. F.J. Palella Jr, R.K. Baker, A.C. Moorman, J.S. Chmiel, K.C. Wood, and J.T. Brooks Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 2006 27 34
12. G.M. Lucas, S.H. Mehta, M.G. Atta, G.D. Kirk, N. Galai, and D. Vlahov End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004 AIDS 21 2007 2435 2443
13. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, and M.W. Steffes National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
14. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
15. V. Shahinian, S. Rajaraman, M. Borucki, J. Grady, W.M. Hollander, and T.S. Ahuja Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients Am J Kidney Dis 35 2000 884 888
16. H. Izzedine, A. Baumelou, and G. Deray Acute renal failure in HIV patients Nephrol Dial Transplant 22 2007 2757 2762
17. L.I. Gardner, S.D. Holmberg, J.M. Williamson, L.A. Szczech, C.C. Carpenter, and A.M. Rompalo Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women J Acquir Immune Defic Syndr 32 2003 203 209
18. J. Roling, H. Schmid, M. Fischereder, R. Draenert, and F.D. Goebel HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy Clin Infect Dis 42 2006 1488 1495
19. T.T. Brown, S.R. Cole, X. Li, L.A. Kingsley, F.J. Palella, and S.A. Riddler Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study Arch Intern Med 165 2005 1179 1184 (Pubitemid 40720744)
20. E.C. Seaberg, A. Munoz, M. Lu, R. Detels, J.B. Margolick, and S.A. Riddler Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003 AIDS 19 2005 953 960
21. H. Izzedine, V. Launay-Vacher, and G. Deray Antiviral drug-induced nephrotoxicity Am J Kidney Dis 45 2005 804 817
22. N. Franceschini, S. Napravnik, W.F. Finn, L.A. Szczech, and J.J. Eron Jr Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients J Acquir Immune Defic Syndr 42 2006 368 372
23. Heffelfinger J, Hanson D, Voetsch A, McNaghten A, Sullivan P. Renal Impairment Associated with the Use of Tenofovir. 13th Conference On Retroviruses and Oportunistic Infections; 2006 Feb 58; Denver, Colorado, EE.UU
24. S.K. Gupta, B.W. Mamlin, C.S. Johnson, M.D. Dollins, J.M. Topf, and M.P. Dube Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients Clin Nephrol 61 2004 1 6
25. M.L. Sorli, A. Guelar, M. Montero, A. González, E. Rodrguez, and H. Knobel Chronic kidney disease prevalence and risk factors among HIV-infected patients J Acquir Immune Defic Syndr 48 2008 506 508
26. S.K. Fernando, F.O. Finkelstein, B.A. Moore, and S. Weissman Prevalence of chronic kidney disease in an urban HIV infected population Am J Med Sci 335 2008 89 94
27. J.T. Cheng, H.L. Anderson Jr., G.S. Markowitz, G.B. Appel, V.A. Pogue, and V.D. D'Agati Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection J Am Soc Nephrol 10 1999 1566 1574
28. E.S. Herman, and P.E. Klotman HIV-associated nephropathy: Epidemiology, pathogenesis, and treatment Semin Nephrol 23 2003 200 208
29. M.H. Humphreys Human immunodeficiency virus-associated glomerulosclerosis Kidney Int 48 1995 311 320
30. V. D'Agati, and G.B. Appel HIV infection and the kidney J Am Soc Nephrol 8 1997 138 152
31. R.J. Glassock, A.H. Cohen, G. Danovitch, and K.P. Parsa Human immunodeficiency virus (HIV) infection and the kidney Ann Intern Med 112 1990 35 49
32. A. Laradi, A. Mallet, H. Beaufils, M. Allouache, and F. Martinez HIV-associated nephropathy: Outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France J Am Soc Nephrol 9 1998 2327 2335
33. V. D'Agati, and G.B. Appel Renal pathology of human immunodeficiency virus infection Semin Nephrol 18 1998 406 421
34. G.M. Lucas, J.A. Eustace, S. Sozio, E.K. Mentari, K.A. Appiah, and R.D. Moore Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study AIDS 18 2004 541 546
35. R.K. Wali, C.I. Drachenberg, J.C. Papadimitriou, S. Keay, and E. Ramos HIV-1-associated nephropathy and response to highly-active antiretroviral therapy Lancet 352 1998 783 784
36. M.G. Atta, J.E. Gallant, M.H. Rahman, N. Nagajothi, L.C. Racusen, and P.J. Scheel Antiretroviral therapy in the treatment of HIV-associated nephropathy Nephrol Dial Transplant 21 2006 2809 2813
37. A. Wei, G.C. Burns, B.A. Williams, N.B. Mohammed, P. Visintainer, and S.L. Sivak Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition Kidney Int 64 2003 1462 1471
38. M.C. Smith, R. Pawar, J.T. Carey, R.C. Graham Jr., G.H. Jacobs, and A. Menon Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy Am J Med 97 1994 145 151
39. D. Nochy, D. Glotz, P. Dosquet, A. Pruna, C. Guettier, and L. Weiss Renal disease associated with HIV infection: A multicentric study of 60 patients from Paris hospitals Nephrol Dial Transplant 8 1993 11 19
40. E. Gutirrez, E. Morales, M.E. Gutirrez, M.J. Manzanares, G. Rosello, and E. Merida Glomerulopathies associated to HIV infection: A Spanish perspective Nefrologia 27 2007 439 447
41. E. Morales, R. Alegre, J.C. Herrero, J.M. Morales, T. Ortuno, and M. Praga Hepatitis-C-virus-associated cryoglobulinaemic membranoproliferative glomerulonephritis in patients infected by HIV Nephrol Dial Transplant 12 1997 1980 1984
42. N. Kamar, L. Rostaing, and L. Alric Treatment of hepatitis C-virus-related glomerulonephritis Kidney Int 69 2006 436 439
43. M. Masia-Canuto, E. Bernal-Morell, and F. Gutirrez-Rodero Lipid alterations and cardiovascular risk associated with antiretroviral therapy Enferm Infecc Microbiol Clin 24 2006 637 648
44. L.A. Szczech, S.K. Gupta, R. Habash, A. Guasch, R. Kalayjian, and R. Appel The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection Kidney Int 66 2004 1145 1152
45. N.J. Weiner, J.W. Goodman, and P.L. Kimmel The HIV-associated renal diseases: Current insight into pathogenesis and treatment Kidney Int 63 2003 1618 1631
46. C.E. Alpers Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy Kidney Int 63 2003 385 396
47. M.F. Gadallah, M.A. El-Shahawy, V.M. Campese, J.R. Todd, and J.W. King Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS Am J Nephrol 16 1996 446 450
48. M.N. Peraldi, C. Maslo, K. Akposso, B. Mougenot, E. Rondeau, and J.D. Sraer Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninety-two patients anad sixty renal biopsies Nephrol Dial Transplant 14 1999 1578 1585
49. D.M. Fine, A.B. Fogo, and C.E. Alpers Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient Semin Nephrol 28 2008 545 555
50. T.E. Gerntholtz, S.J. Goetsch, and I. Katz HIV-related nephropathy: A South African perspective Kidney Int 69 2006 1885 1891
51. E. Morales, E. Gutirrez-Solis, E. Gutirrez, R. González, M.A. Martnez, and M. Praga Malignant hypertension in HIV-associated glomerulonephritis Nephrol Dial Transplant 23 2008 3901 3907
52. B.L. Clarke, A.G. Wynne, D.M. Wilson, and L.A. Fitzpatrick Osteomalacia associated with adult Fanconi's syndrome: Clinical and diagnostic features Clin Endocrinol (Oxf) 43 1995 479 490
53. H. Izzedine, V. Launay-Vacher, C. Isnard-Bagnis, and G. Deray Drug-induced Fanconi's syndrome Am J Kidney Dis 41 2003 292 309
54. S.K. Gupta Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system AIDS Patient Care STDS 22 2008 99 103
55. C.W. James, M.C. Steinhaus, S. Szabo, and R.M. Dressier Tenofovir-related nephrotoxicity: Case report and review of the literature Pharmacotherapy 24 2004 415 418
56. M. Nelson, A. Azwa, A. Sokwala, R.S. Harania, and J. Stebbing Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy AIDS 22 2008 1374 1376
57. G. D'Ythurbide, C. Goujard, F. Mechai, A. Blanc, B. Charpentier, and R. Snanoudj Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: A case report and literature review Nephrol Dial Transplant 22 2007 3656 3659
58. M.R. Nelson, C. Katlama, J.S. Montaner, D.A. Cooper, B. Gazzard, and B. Clotet The safety of tenofovir disoproxil fuMaríate for the treatment of HIV infection in adults: The first 4 years AIDS 21 2007 1273 1281
59. M. Goicoechea, S. Liu, B. Best, S. Sun, S. Jain, and C. Kemper Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy J Infect Dis 197 2008 102 108
60. S. Padilla, F. Gutirrez, M. Masi, V. Cnovas, and C. Orozco Low frequency of renal function impairment during 1-year therapy with tenofovir-containing regimens in the real-world scenario: A case-control study AIDS Patient Care STD 19 2005 421 424
61. H.M. Crane, B. Kestenbaum, R.D. Harrington, and M.M. Kitahata Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir AIDS 21 2007 1431 1439
62. M. Masia, F. Gutirrez, S. Padilla, J.M. Ramos, and J. Pascual Severe toxicity associated with the combination of tenofovir and didanosine: Case report and review Int J STD AIDS 16 2005 646 648
63. J.J. Kiser, M.L. Carten, C.L. Aquilante, P.L. Anderson, P. Wolfe, and T.M. King The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients Clin Pharmacol Ther 83 2008 265 272
64. H. Izzedine, J.S. Hulot, E. Villard, C. Goyenvalle, S. Domnguez, and J. Ghosn Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy J Infect Dis 194 2006 1481 1491
65. J.J. Kiser, C.L. Aquilante, P.L. Anderson, T.M. King, M.L. Carten, and C.V. Fletcher Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients J Acquir Immune Defic Syndr 47 2008 298 303
66. S. Rodrguez Novoa, P. Labarga, V. Soriano, D. Egan, M. Albalater, and J. Morello Predictors of kidney tubular disfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study Clin Infect Dis 48 2009 e108 e116
67. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
68. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
69. A.S. Levey, J. Coresh, T. Greene, L.A. Stevens, Y.L. Zhang, and S. Hendriksen Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate Ann Intern Med 145 2006 247 254
70. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, and L.L. Hamm Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 2003 1050 1065 (Pubitemid 37413751)
71. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
72. J. Coresh, B. Astor, and M.J. Sarnak Evidence for increased cardiovascular disease risk in patients with chronic kidney disease Curr Opin Nephrol Hypertens 13 2004 73 81
73. S.L. Day, H.A. Leake Date, A. Bannister, M. Hankins, and M. Fisher Serum hypophosphatemia in tenofovir disoproxil fuMaríate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice J Acquir Immune Defic Syndr 38 2005 301 304
74. J.M. Ginsberg, B.S. Chang, R.A. Matarese, and S. Garella Use of single voided urine samples to estimate quantitative proteinuria N Engl J Med 309 1983 1543 1546
75. J. Amanzadeh, and J.F. Reilly Jr Hypophosphatemia: An evidence-based approach to its clinical consequences and management Nat Clin Pract Nephrol 2 2006 136 148
76. B.C. Isnard, S.T. Du Montcel, M. Fonfrede, M.C. Jaudon, V. Thibault, and G. Carcelain Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era Nephron Physiol 103 2006 131 138
77. D.S. Keith, G.A. Nichols, C.M. Gullion, J.B. Brown, and D.H. Smith Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization Arch Intern Med 164 2004 659 663
78. T.H. Jafar, P.C. Stark, C.H. Schmid, M. Landa, G. Maschio, and P.E. de Jong Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis Ann Intern Med 139 2003 244 252
79. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 2004 S1 S290
80. S. Mandayam, and T.S. Ahuja Dialyzing a patient with human immunodeficiency virus infection: What a nephrologist needs to know Am J Nephrol 24 2004 511 521
81. European best practice guidelines for haemodialysis. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant 2002; 17: 7287
82. J. Tourret, I. Tostivint, S.T. Du Montcel, J. Bragg-Gresham, S. Karie, and C. Vigneau Outcome and prognosis factors in HIV-infected hemodialysis patients Clin J Am Soc Nephrol 1 2006 1241 1247
83. M.E. Roland, B. Barin, L. Carlson, L.A. Frassetto, N.A. Terrault, and R. Hirose HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes Am J Transplant 8 2008 355 365
84. G.M. Rivera, J.L. Merino Rivas, M.C. Arcon Garcelan, A.C. Galeano, O. Manuel, and J.L. Teruel Briones Outcome of HIV-infected patients of peritoneal dialysis: Experience in a center and literature review Nefrologia 28 2008 505 510
85. C. Lucas, F. Carrera, C. Jorge, H. Boquinhas, and M.J. Pais Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients Nephrol Dial Transplant 21 2006 3202 3206
86. P.C. Oberai, D. Dalal, L. Zhang, C. Wang, J. Eustace, and R.S. Parekh Incidence of atherosclerotic cardiovascular disease among HIV patients receiving dialysis Am J Kidney Dis 47 2006 848 855
87. G. Barril, J.C. Trullas, E. González-Parra, A. Moreno, E. Bergada, and R. Jofr Prevalence of HIV-1-infection in dialysis units in Spain and potential candidates for renal transplantation: Results of a Spanish survey Enferm Infecc Microbiol Clin 23 2005 335 339
88. 2008 prevention of opportunistic infections in HIV-infected adolescents and adults guidelines. Recommendations of GESIDA/National AIDS Plan AIDS Study Group (GESIDA) and National AIDS Plan Enferm Infecc Microbiol Clin 26 2008 437 464
89. J.C. Trullas, J.M. Miro, G. Barril, S. Ros, F.J. Burgos, and A. Moreno Renal transplantation in patients with HIV infection Enferm Infecc Microbiol Clin 23 2005 363 374
90. J.M. Miro, J. Torre-Cisneros, A. Moreno, M. Tuset, C. Quereda, and M. Laguno GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005) Enferm Infecc Microbiol Clin 23 2005 353 362
91. P.C. Kuo, and P.G. Stock Transplantation in the HIV patient Am J Transplant 1 2001 13 17
92. M.E. Roland, and P.G. Stock Review of solid-organ transplantation in HIV-infected patients Transplantation 75 2003 425 429
93. K.C. Abbott, S.J. Swanson, L.Y. Agodoa, and P.L. Kimmel Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression J Am Soc Nephrol 15 2004 1633 1639
94. J. Qiu, P.I. Terasaki, K. Waki, J. Cai, and D.W. Gjertson HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients Transplantation 81 2006 1658 1661
95. L.A. Frassetto, M. Browne, A. Cheng, A.R. Wolfe, M.E. Roland, and P.G. Stock Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients Am J Transplant 7 2007 2816 2820
96. G.A. Knoll, M.R. Tankersley, J.Y. Lee, B.A. Julian, and J.J. Curtis The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients Am J Kidney Dis 29 1997 608 614
97. S.A. Gruber, M.D. Doshi, E. Cincotta, K.L. Brown, A. Singh, and K. Morawski Preliminary experience with renal transplantation in HIV recipients: Low acute rejection and infection rates Transplantation 86 2008 269 274
98. J.T. Carter, M.L. Melcher, L.L. Carlson, M.E. Roland, and P.G. Stock Thymoglobulin-associated Cd4 T-cell depletion and infection risk in HIV-infected renal transplant recipients Am J Transplant 6 2006 753 760
99. J.C. Trullas, F. Cofan, S. Cocchi, C. Cervera, L. Linares, and F. Aguero Effect of thymoglobulin induction on HIV-infected renal transplant recipients: Differences between HIV-positive and HIV-negative patients AIDS Res Hum Retroviruses 23 2007 1161 1165
100. L.A. Szczech, R. Kalayjian, R. Rodrguez, S. Gupta, J. Coladonato, and J. Winston The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis Kidney Int 63 2003 2295 2301
101. Zerit, Package Insert (Rev September 2007).
102. D.M. Grasela, R.R. Stoltz, M. Barry, M. Bone, B. Mangold, and P. O'Grady Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis Antimicrob Agents Chemother 44 2000 2149 2153
103. C.A. Knupp, L.J. Hak, D.F. Coakley, R.J. Falk, B.E. Wagner, and R.H. Raasch Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis Clin Pharmacol Ther 60 1996 535 542
104. E. Singlas, A.M. Taburet, L.F. Borsa, O. Parent de Curzon, A. Sobel, and P. Chauveau Didanosine pharmacokinetics in patients with normal and impaired renal function: Influence of hemodialysis Antimicrob Agents Chemother 36 1992 1519 1524
105. F. Bonnet, M. Bonarek, P. Morlat, P. Mercie, M. Dupon, and M.C. Gemain Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: A case-control study Clin Infect Dis 36 2003 1324 1328
106. M. Masi, F. Gutirrez, S. Padilla, J.M. Ramos, and J. Pascua Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and Didanosine? J Acquir Immune Defic Syndr 35 2004 427 428
107. H. Izzedine, V. Launay-Vacher, A. Baumelou, and G. Deray An appraisal of antiretroviral drugs in hemodialysis Kidney Int 60 2001 821 830
108. H. Izzedine, V. Launay-Vacher, G. Aymard, M. Legrand, and G. Deray Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function Nephron 89 2001 62 67
109. B.P. Kearney, K. Yale, J. Shah, L. Zhong, and J.F. Flaherty Pharmacokinetics and dosing recommendations of tenofovir disoproxil fuMaríate in hepatic or renal impairment Clin Pharmacokinet 45 2006 1115 1124
110. H. Izzedine, V. Launay-Vacher, V. Jullien, G. Aymard, C. Duvivier, and G. Deray Pharmacokinetics of tenofovir in haemodialysis Nephrol Dial Transplant 18 2003 1931 1933
111. Tenofovir, Package Insert (Rev September 2007).
112. J. Jao, and C.M. Wyatt Antiretroviral medications: adverse effects on the kidney Adv Chronic Kidney Dis 17 2010 72 82
113. P.F. Smith, R. DiCenzo, and G.D. Morse Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors Clin Pharmacokinet 40 2001 893 905
114. H. Izzedine, V. Launay-Vacher, G. Aymard, M. Legrand, and G. Deray Pharmacokinetic of nevirapine in haemodialysis Nephrol Dial Transplant 16 2001 192 193
115. A.M. Taburet, L. Gerard, M. Legrand, G. Aymard, and J.M. Berthelot Antiretroviral drug removal by haemodialysis AIDS 14 2000 902 903
116. H. Izzedine, V. Launay-Vacher, and G. Deray Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis Nephrol Dial Transplant 16 2001 643
117. S. Taylor, J. Little, K. Halifax, S. Drake, and D. Back Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis J Antimicrob Chemother 45 2000 716 717
118. M.J. Gill, N.J. Ostrop, W.D. Fiske, and J.M. Brennan Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis AIDS 14 2000 1062 1064
119. H. Izzedine, G. Aymard, V. Launay-Vacher, A. Hamani, and G. Deray Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis AIDS 14 2000 618 619
120. M. Barry, S. Gibbons, D. Back, and F. Mulcahy Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations Clin Pharmacokinet 32 1997 194 209
121. H. Izzedine, G. Aymard, A. Hamani, V. Launay-Vacher, and G. Deray Indinavir pharmacokinetics in haemodialysis Nephrol Dial Transplant 15 2000 1102 1103
122. H. Izzedine, V. Launay-Vacher, G. Peytavin, M.A. Valantin, and G. Deray Atazanavir: A novel inhibitor of HIV-protease in haemodialysis Nephrol Dial Transplant 20 2005 852 853
123. Agarwala S, Eley T, Child M, Wang Y, Persson A, Filoramo D. Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. 8th International Worshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16-18; Budapest, Hungary.
124. Gigure P, La Porte C, Zhang G, Cameron B. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis. AIDS; 23:740-2
125. Prezista, Package Insert (Rev February 2007).
126. I.H. Patel, X. Zhang, K. Nieforth, M. Salgo, and N. Buss Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide Clin Pharmacokinet 44 2005 175 186
127. C. Leen, C. Wat, and K. Nieforth Pharmacokinetics of enfuvirtide in a patient with impaired renal function Clin Infect Dis 39 2004 e119 e121
128. P. Tebas, N. Bellos, C. Lucasti, G. Richmond, E. Godofsky, and I. Patel Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: Results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function J Acquir Immune Defic Syndr 47 2008 342 345
129. Raltegravir, Package Insert (Rev May 2009).
130. M. Iwamoto, W.D. Hanley, A.S. Petry, E.J. Friedman, J.T. Kost, and S.A. Breidinger Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics Antimicrob Agents Chemother 53 2009 1747 1752
131. E. DeJesus, D. Berger, M. Markowitz, C. Cohen, T. Hawkins, and P. Ruane Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients J Acquir Immune Defic Syndr 43 2006 1 5
132. Maríaviroc, Package Insert (Rev February 2008).
133. P.E. Kintzel, and R.T. Dorr Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function Cancer Treat Rev 21 1995 33 64
134. European Medicines Agency (EMEA) 2005. European public assessment report on Pegasys (Rev 2) [consultado [16/04/2007]. 2007.
135. European Medicines Agency (EMEA) 2005. European public assessment report on PegIntron (Rev 5) [consultado [16/06/07]. 2009.
136. Copegus, Package Insert (Rev September 2007)
137. S.K. Gupta, J.A. Eustace, J.A. Winston, I.I. Boydstun, T.S. Ahuja, and R.A. Rodriguez Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Clin Infect Dis 40 2005 1559 1585
138. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease Am J Kidney Dis 41 2003 1 91
139. J. Nogueira, and M. Weir The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs Clin J Am Soc Nephrol 2 2007 766 785
140. B.L. Kasiske Hyperlipidemia in patients with chronic renal disease Am J Kidney Dis 32 1998 S142 S156
141. B. Kasiske, F.G. Cosio, J. Beto, K. Bolton, B.M. Chavers, and R. Grimm Jr. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Am J Transplant 4 2004 13 53
142. R.H. Stern, B.B. Yang, M. Horton, S. Moore, R.B. Abel, and S.C. Olson Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin J Clin Pharmacol 37 1997 816 819
143. R.W. Snyder, and J.S. Berns Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease Semin Dial 17 2004 365 370
144. K. Rave, T. Heise, A. Pfutzner, L. Heinemann, and P.T. Sawicki Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients Diabetes Care 24 2001 886 890
145. Glucophage Package Insert (Rev June 2001)
146. J. Krepinsky, A.J. Ingram, and C.M. Clase Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease Am J Kidney Dis 35 2000 500 505
147. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 49 2007 S12 S154
148. K. Thompson-Culkin, B. Zussman, A.K. Miller, and M.I. Freed Pharmacokinetics of rosiglitazone in patients with end-stage renal disease J Int Med Res 30 2002 391 399
149. M.C. Chapelsky, K. Thompson-Culkin, A.K. Miller, M. Sack, R. Blum, and M.I. Freed Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency J Clin Pharmacol 43 2003 252 259
150. P. Mohideen, M. Bornemann, J. Sugihara, V. Genadio, V. Sugihara, and R. Arakaki The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease Endocrine 28 2005 181 186
151. G. Villanueva, and D. Baldwin Rosiglitazone therapy of posttransplant diabetes mellitus Transplantation 80 2005 1402 1405
152. M.J. Glesby, J.A. Aberg, M.A. Kendall, C.J. Fichtenbaum, R. Hafner, and S. Hall Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers Clin Pharmacol Ther 78 2005 143 153